{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Left Inguinal Region"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Left Iliac Region"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Right Iliac Region"}],"denomUnitsSelected":"sentinel lymph nodes (SLNs)","denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"17"}],"units":"sentinel lymph nodes (SLNs)"}],"groups":[{"description":"Patients receive perflubutane microbubble injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment.\n\nPerflubutane Microbubble: Given subdermally\n\nContrast-Enhanced Ultrasound: Undergo ultrasound","id":"OG000","title":"Diagnostic (Perflubutane Microbubble, Ultrasound)"}],"paramType":"NUMBER","populationDescription":"Only participants who completed CEUS and surgery (N=5) were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 30 minutes during CEUS procedure","title":"Location of Sentinel Lymph Nodes (SLNs) Identified by Contrast-enhanced Ultrasound (CEUS)","type":"SECONDARY","typeUnitsAnalyzed":"sentinel lymph nodes (SLNs)","unitOfMeasure":"sentinel lymph nodes (SLNs)"}